Atrophy of salivary gland
ICD-10 K11.0 is a billable code used to indicate a diagnosis of atrophy of salivary gland.
Atrophy of the salivary gland, classified under ICD-10 code K11.0, refers to the reduction in size and function of the salivary glands, which can lead to decreased saliva production. Clinically, patients may present with dry mouth (xerostomia), difficulty swallowing (dysphagia), and increased dental caries due to reduced oral moisture. The major salivary glands involved include the parotid, submandibular, and sublingual glands. Atrophy can result from various etiologies, including autoimmune disorders (such as Sjögren's syndrome), radiation therapy, chronic inflammation, and certain medications. Disease progression may lead to significant oral health issues, impacting nutrition and quality of life. Diagnostic considerations include a thorough patient history, physical examination, and imaging studies such as sialography or ultrasound to assess gland structure and function. Salivary flow rate tests may also be employed to quantify saliva production, aiding in the diagnosis of atrophy.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
K11.0 covers conditions leading to atrophy of the salivary glands, primarily due to autoimmune diseases, radiation exposure, or chronic inflammation. It is important to differentiate it from other salivary gland disorders such as infections or obstructions.
K11.0 should be used when there is a confirmed diagnosis of salivary gland atrophy, particularly when accompanied by symptoms of dry mouth and reduced saliva production, distinguishing it from conditions like sialadenitis or sialolithiasis.
Documentation should include a detailed patient history, clinical findings of xerostomia, results from salivary flow tests, and any imaging studies performed. Evidence of underlying conditions contributing to gland atrophy should also be documented.
